Skip to main content

Table 3 Results of multilevel analyses: Assessment (t0-t1) vs. standard treatment (t1-t3) vs. extended treatment (t3-t10)

From: Extended treatment of multimodal cognitive behavioral therapy in children and adolescents with obsessive–compulsive disorder improves symptom reduction: a within-subject design

  

Change during assessment

Change during standard treatment

Change during extended treatment

  

Phase 1: t0-t1

Phase 2 and 3: t1-t3

Phase 3a: t3-t5

Phase 3b: t5-t7

Phase 3c: t7-t9

Phase 3d: t9-t10

Outcome

n

β (CI 95%)

ES

β (CI 95%)

ES

β (CI 95%)

ES

β (CI 95%)

ES

β (CI 95%)

ES

β (CI 95%)

ES

CY-BOCS-D rating scale

             
 

38

− 0.34a (− 0.69 to 0.01)

− 0.48

− 0.54***b,c (− 0.72 to − 0.36)

− 1.53

− 0.42***a,c (− 0.61 to − 0.24)

− 1.19

− 0.05b,d (− 0.25 to 0.16)

− 0.14

− 0.08b,d (− 0.33 to 0.16)

− 0.23

− 0.06a,c (− 0.62 to 0.49)

− 0.09

Obsession severity

38

− 0.18a (− 0.40 to 0.04)

− 0.25

− 0.23***a,c (− 0.35 to − 0.12)

− 0.66

− 0.17**a,c (− 0.28 to − 0.05)

− 0.47

− 0.07a,d (− 0.19 to 0.06)

− 0.18

0.01b,d (− 0.14 to 0.16)

0.03

− 0.13a,c (− 0.47 to 0.21)

− 0.18

Compulsion severity

38

− 0.18*a (− 0.36 to − 0.00)

− 0.49

− 0.29***b,c (− 0.38 to − 0.20)

− 1.56

− 0.22***a,c (− 0.32 to − 0.13)

− 1.21

0.01b,d (− 0.09 to 0.11)

0.05

− 0.06b,d (− 0.18 to 0.07)

− 0.31

− 0.05a,c (− 0.32 to 0.23)

− 0.12

OCD-CA

             

Total OCD symptoms

[31]

[− 0.32a] [(− 1.20 to 0.56)]

[− 0.11]

[− 0.53*a,c] [(− 0.97 to − 0.10)]

[− 0.38]

[− 0.65**a,c] [(− 1.09 to − 0.21)]

[− 0.46]

[− 0.42a,c] [(− 0.91 to 0.06)]

[− 0.30]

[− 0.03a,c] [(− 0.59 to 0.53)]

[− 0.02]

[0.70a,c] [(− 0.61 to 2.01)]

[0.25]

{37}

{− 0.72a} {(− 1.48 to 0.04)}

{− 0.25}

{− 0.56**a,c} {(− 0.96 to − 0.16)}

{− 0.40}

{− 0.73***a,c} {(− 1.13 to − 0.32)}

{− 0.51}

{− 0.03b,d} {(− 0.48 to 0.43)}

{− 0.02}

{− 0.09b,c} {(− 0.62 to 0.45)}

{− 0.06}

{0.25a,c} {(− 0.98 to 1.49)}

{0.09}

OCD-related problem list

             

Frequency

[31]

[− 0.04*a] [(− 0.08 to − 0.00)]

[− 0.23]

[− 0.05***a,c] [(− 0.06 to − 0.04)]

[− 0.57]

[− 0.04***a,c] [(− 0.05 to − 0.03)]

[− 0.47]

[− 0.02***b,d] [(− 0.03 to − 0.01)]

[− 0.25]

[− 0.01b,d] [(− 0.03 to 0.00)]

[− 0.17]

[0.06**b,d] [(0.02 to 0.10)]

[0.36]

{32}

{− 0.01a} {(− 0.05 to 0.04)}

{− 0.04}

{− 0.06***b,c} {(− 0.08 to − 0.04)}

{− 0.90}

{− 0.04***b,d} {(− 0.06 to − 0.02)}

{− 0.62}

{0.00a,d} {(− 0.02 to 0.02)}

{− 0.05}

{− 0.01a,d} {(− 0.03 to 0.01)}

{− 0.16}

{− 0.02a,c} {(− 0.08 to 0.05)}

{− 0.14}

Strain

[31]

[− 0.12**a] [(− 0.21 to − 0.03)]

[− 0.39]

[− 0.07***b,c] [(− 0.10 to − 0.04)]

[− 0.46]

[− 0.11***a,d] [(− 0.14 to − 0.09)]

[− 0.73]

[− 0.04**b,c] [(− 0.07 to − 0.01)]

[− 0.28]

[− 0.01b,d] [(− 0.05 to 0.02)]

[− 0.09]

[0.01b,d] [(− 0.05 to 0.16)]

[0.18]

{32}

{− 0.13*a} {(− 0.25 to − 0.01)}

{− 0.49}

{− 0.11***a,c} {(− 0.15 to − 0.06)}

{− 0.81}

{− 0.10***a,c} {(− 0.14 to − 0.06)}

{− 0.77}

{0.00b,d} {(− 0.04 to 0.05)}

{0.04}

{− 0.03b,d} {(− 0.09 to 0.03)}

{− 0.25}

{0.09b,d} {(− 0.07 to 0.25)}

{0.34}

Psychosocial impairment

[30]

[− 0.06***a] [(− 0.10 to − 0.03)]

[− 0.36]

[− 0.03***b,c] [(− 0.04 to − 0.02)]

[− 0.36]

[− 0.02***b,c] [(− 0.03 to − 0.01)]

[− 0.25]

[− 0.01b,d] [(− 0.02 to 0.01)]

[− 0.06]

[0.00b,d] [(− 0.01 to 0.01)]

[0.00]

[0.00b,c] [(− 0.03 to 0.04)]

[0.03]

{36}

{− 0.03a} {(− 0.07 to 0.01)}

{− 0.26}

{− 0.05***b,c} {(− 0.07 to − 0.04)}

{− 0.82}

{− 0.02*b,d} {(− 0.03 to − 0.00)}

{− 0.28}

{0.00b,d} {(− 0.02 to 0.02)}

{0.05}

{0.00b,d} {(− 0.02 to 0.03)}

{0.04}

{− 0.04a,c} {(− 0.10 to 0.02)}

{− 0.29}

OCD-functional impairment list

             

Total psychosocial impairment

[30]

[− 1.35***a] [(− 1.64 to − 1.05)]

[− 0.57]

[− 0.36***b,c] [(− 0.46 to − 0.27)]

[− 0.31]

[− 0.26***b,d] [(− 0.35 to − 0.18)]

[− 0.22]

[− 0.10*b,d] [(− 0.19 to − 0.01)]

[− 0.09]

[− 0.17**b,d] [(− 0.28 to − 0.05)]

[− 0.14]

[0.27b,d] [(− 0.08 to 0.61]

[0.11]

{35}

{− 1.52***a} {(− 2.01 to − 1.03)}

{− 0.80}

{− 0.56***b,c} {(− 0.75 to − 0.37)}

{− 0.59}

{− 0.19*b,d} {(− 0.38 to 0.00)}

{− 0.20}

{− 0.03b,d} {(− 0.25 to 0.18)}

{− 0.04}

{− 0.43**b,c} {(− 0.70 to − 0.16)}

{− 0.45}

{0.13b,c} {(− 0.60 to 0.86)}

{0.07}

  1. n sample size, β slope, CI confidence interval, ES effect size; bold values show the results of the primary outcome; clinical rating, [self-report], {parent report};*p≤.05, **p≤.01, ***p≤.001; a,b,c,dslopes with superscripts (a) do not differ significantly from assessment phase, slopes with superscript (b) differ significantly at a level of ≤.05 from assessment phase; slopes with superscripts (c) do not differ significantly from standard treatment phase, slopes with superscript (d) differ significantly at a level of ≤.05 from standard treatment phase